Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease

 Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease

Shots:

  • Mestag to receive option fees, milestones, royalties and will deploy its specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets
  • Janssen to get an option to exclusive license to develop and commercialize therapies directed against up to two targets emerges from the collaboration
  • Apart from this collaboration, Mestag will continue to develop its inflammatory disease and cancer programs as it progresses its pipeline of first-in-class therapeutics towards the clinic

Click here to­ read full press release/ article | Ref: Mestag Therapeutics | Image: Mestag Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post